Eli Lilly to Invest Over $1 Billion in India to Boost Manufacturing Capacity

Global pharmaceutical major Eli Lilly announced plans to invest more than $1 billion in India over the coming years to expand manufacturing and supply operations through local drugmakers. The move is part of Lilly’s broader strategy to strengthen global production and leverage India’s skilled pharmaceutical workforce.

Focus on Key Therapeutic Areas and Local Partnerships

The investment will enhance the availability of Lilly’s key treatments for obesity, diabetes, Alzheimer’s, cancer, and autoimmune conditions. While the company currently does not have its own manufacturing unit in India, it is actively collaborating with Indian contract manufacturers that specialize in complex formulations, injectables, and vials.

India’s Role in Lilly’s Global Expansion Strategy

Patrik Jonsson, President of Lilly International, said the investment underscores India’s importance as a global hub for manufacturing and capability building. Following the recent launch of its blockbuster weight-loss drug Mounjaro in India, Lilly’s partnerships are expected to significantly boost the country’s role in the company’s global supply chain.